Basel is the most dynamic economic region in Switzerland and one of the most productive and innovative locations worldwide. Global leaders in the life sciences industry – Novartis, Roche, Syngenta, Lonza and others – have their headquarters in the Basel region. Basel is considered one of Europe’s top locations for life sciences and healthcare. This stimulating environment has given rise to a plethora of innovative research firms, including in the medical and biotechnology fields.
Novo Holdings established the REPAIR Impact Fund commissioned by the Novo Nordisk Foundation in February 2018 with a total budget of USD 165 million to invest in companies involved in discovering and the early-stage development of therapies targeting resistant microorganisms.
The fund is expected to invest USD 20 million to 40 million per year over 3–5 years in about 20 projects, which is anticipated to yield at least one new therapy reaching the market.
The REPAIR Impact Fund will invest in start-ups, early-stage companies and corporate spin-outs. Our philosophy is to support ambitious programmes addressing antimicrobial resistance through a broad range of therapeutic modalities.
REPAIR is an acronym: Replenishing and Enabling the Pipeline for Anti-Infective Resistance.
BioVersys AG focuses on life threatening infectious diseases. As a privately owned clinical stage Swiss pharmaceutical company working on research & development of small molecules acting on novel bacterial targets, BioVersys addresses the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. Our most advanced programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 2-ready), and tuberculosis (BVL-GSK098, Phase 2a) in collaboration with GSK and a consortium of the University of Lille.
INCATE brings together translational and basic research, industry, experienced entrepreneurs and investors from across Europe to accelerate your innovation. We do this by providing advice, community and funding. Our focus is on the development of new therapies, diagnostics and interventions that help reduce the prevalence and impact of Antimicrobial Resistance (AMR).
The National Center of Competence in Research AntiResist aims to bring about a paradigm shift in antibiotic research with an interdisciplinary approach that assembles a Swiss-wide network of research groups from the fields of clinical research, biology, chemistry, computation, engineering and pharmacology.
The research program is structured into three four-year phases covering strategically and dynamically evolving milestones. Research activities center around a better understanding of pathogen physiology in patients; developing axenic and tissue-based model systems mimicking patient environments; and engineering of novel screening platforms for the next generation of antibiotics.
The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant infections. Together with private, public and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come.
Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within the areas of drug discovery and drug development studies.
Selvita was established in 2007 and currently employs over 1000 professionals, of which over 40% hold a PhD degree. The Company research sites are located in Krakow (HQ) and Poznan, Poland, as well as Zagreb, Croatia.
Selvita Group has broad expertise and track record in oncology, inflammation, fibrosis, anti-infectives, respiratory diseases and CNS. If you want to learn more about our services, visit our website.
LEIBNIZ HEALTH TECHNOLOGIES: A Research Alliance of the Leibniz Association
Providing technological solutions for unmet medical needs − this is the main focus of the 19 members of the interdisciplinary research alliance Leibniz Health Technologies.
To battle antimicrobial resistances, 16 Leibniz institutes and 3 spin-off companies are cooperating in developing e.g. the “RamanBioAssay”, a photonics-based test to determine the efficacy of antibiotics (MIC) in less than 4 hours. The alliance is also inventing therapeutic devices based on cold atmospheric plasma, which is a suitable technology for deactivating various types of microorganisms, including multi-resistant bacteria such as MRSA.
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. Basilea is committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. The company has successfully developed and launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, Basilea has preclinical anti-infective assets in its portfolio and is listed on the SIX Swiss Exchange (SIX: BSLN). More on basilea.com.
Our dedication to public health is the thread that connects everything we do.
It connects us to our history – since 1963, we have been fulfilling the vision of the Mérieux family to improve health, while maintaining the values of respect, accountability, transparency, and sharing. Building on our strong legacy, we understand that our expertise in infectious diseases and our international presence give us a special duty to act as a responsible corporate citizen, serving the greater good and the community.
This commitment also connects us with our environment – infectious diseases are one of the major threats to human kind. Their emergence and spread are dramatically accelerated by climate change and globalization. The risk of finding ourselves unarmed to face ultra-resistant bacteria is now a reality.
Diagnostics is a game changer in this fight. By pioneering diagnostic solutions, we help clinicians improve patient care and we help industries prevent contamination of the food and pharmaceuticals they produce. At bioMérieux we are convinced that, only by taking into account our entire ecosystem and the public interest, will we be able to succeed in building a healthier world and a more inclusive society.
We are bioMérieux. We act for a positive impact. We act for a healthier world.
At the German Center for Infection Research (DZIF), about 500 researchers from 35 institutions throughout Germany jointly develop new approaches for the prevention, diagnosis and treatment of infectious diseases. The aim of this nationwide collaboration between universities, hospitals and research institutions is to translate research results into clinical practice quickly and effectively. With this, the DZIF paves the way for developing new vaccines, diagnostic agents and drugs to treat infections.
Resistell AG is a clinical-stage company transforming the landscape of Antibiotic Susceptibility Testing (AST) with the world’s fastest AST platform based on proprietary nanomotion technology for measuring induced metabolic changes in living. Resistell Phenotech AST is a CE IVD certified rapid AST in bloodstream infections with a time-to-result of 4 hours. The 2nd generation device enabling an ultra-rapid AST of only 2 hours is already available. In addition to the diagnostic product, Resistell offers Phenotech Research, a globally available research device for exploring new applications.
At the InfectoGnostics Research Campus, diagnostic methods are developed and combined to reliably detect infectious agents and antibiotic resistance and to better understand the host response. Connecting basic research, development and application at an early stage results in market-ready laboratory and point-of-care-tests for use in human and veterinary medicine as well as for environmental/water and food analysis. More than 30 partners from science, medicine and industry are working together on novel solutions for the rapid and cost-effective diagnosis of infectious diseases.
Further information can be found at: https://www.infectognostics.de/en/
Youtube video: https://www.youtube.com/watch?v=7-RD6yB-iYU&t=43s
AUROBAC THERAPEUTICS is a biopharmaceutical company founded as a joint venture by Boehringer Ingelheim, Evotec and bioMérieux, to create the next generation of products to fight difficult-to-treat infectious diseases and AntiMicrobial Resistance (AMR). Our goal is to develop precision medicines, using new highly effective and targeted modalities, combined with rapid and actionable diagnostics. We will cover the entire value chain of projects from R&D, including clinical development, to registration and commercialization.
AUROBAC is currently seeking to strengthen its product portfolio and is particularly interested in in-licensing/co-developing innovative products developed to fight bacterial infections & AMR.
Together, we are driving innovation in Thuringia: As Thuringian Cluster Management (ThCM), we support companies, research and science institutions in Thuringia to work better together. In doing so, we manage the implementation process of the Regional Innovation Strategy for Smart Specialisation and Economic Change in Thuringia (RIS Thüringen).
Our experienced field of specialisation managers work closely with stakeholders from business, academia and intermediaries to advance the development of the fields of specialisation. Our aim is to forge sustainable links between a wide range of disciplines and actors who together expand, strengthen and inspire innovation in Thuringia.
In addition to organising and implementing events, workshops and trade fairs, we support clusters and networks in raising their profile. We provide information about current funding programmes of the region, the federal government and the EU and accompany projects from their idea to the funded project. In doing so, we support the stakeholders in initiating, moderating and coordinating strategically important projects.
Launched in June 2015, the BEAM Alliance (Biotech companies from Europe innovating in Anti-Microbial resistance research) represents over 70 small and medium-sized European companies involved in developing innovative products and kits to tackle antimicrobial resistance (AMR), including small molecule antibiotics, biologics, products with a prophylaxis indication, microbiome-based and phage-based therapies, immune targeting therapies, anti-biofilm agents and medical devices including in vitro diagnostics.
BEAM collaborates with the existing community of stakeholders dedicated to implementing tangible strategies. BEAM gives its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe. BEAM recommends bold incentives that warrant action by policymakers to stimulate much needed innovation.
The Swiss Biotech Association is a non-profit, member-driven organization representing the interests of the Swiss biotech industry. Swiss biotech companies are leading the way in developing and commercializing innovative medicines, diagnostics, healthcare treatments, services and enabling technologies.
Our core objective is to ensure that the value generated by the Swiss biotech industry continues to grow and that the industry contributes to the well-being of the socio-economic ecosystem thereby enabling Switzerland to be a key player at the forefront of bioscience innovation.